Peripheral immune mechanism: In tauopathy mice, lymph-node classical type 1 dendritic cells (cDC1s) activate CD8 T cells; those T cells then enter the brain and contribute to neurodegeneration. Removing or blocking cDC1s markedly reduced neurodegeneration and preserved cognitive performance despite persistence of tau pathology/tangles. 9

Interpretation: This dissociates the burden of tau aggregates from downstream tissue injury and cognition. Tau may establish the disease substrate, while adaptive immune attack helps determine how much neuronal and synaptic damage follows. Earlier mouse work likewise found that eliminating T cells or microglia blocked tau-associated neurodegeneration. 6

Dendritic tau quality control: A second study identifies a neuron-specific surface proteasome—the “neuroproteasome”—as a critical controller of tau proteostasis and tau paired-helical-filament formation, with effects influenced by age and APOE genotype. 2 Complementary work using single-molecule translation imaging shows endogenous mRNA translation can be mapped in dendrites in neurons and in vivo, supporting the central importance of local dendritic protein handling. 1

Act outside the brain: In principle, therapies could inhibit cDC1 antigen presentation, the cDC1–CD8 activation axis, or the migration/survival of the pathogenic CD8 population in peripheral lymph nodes. Such drugs might not need to cross the blood–brain barrier, potentially making delivery easier than CNS-targeted drugs. This remains a mouse-model implication—not an established Alzheimer’s treatment. 9

Preserve local tau disposal: A separate strategy would be to maintain or enhance dendritic neuroproteasome function, preventing locally synthesized tau from escaping rapid degradation and forming pathogenic assemblies. Because proteasomes have essential roles throughout the body, any approach would need neuron-, compartment-, and substrate-selective targeting rather than indiscriminate proteasome stimulation. 2

Combine mechanisms: The logic supports a two-pronged approach: reduce tau production/aggregation or improve its clearance, while also preventing peripheral immune priming from converting tau pathology into CD8-mediated brain damage. The studies do not yet establish whether either intervention is safe, effective, or durable in people.

Peripheral immune mechanism: In tauopathy mice, lymph-node classical type 1 dendritic cells (cDC1s) activate CD8 T cells; those T cells then enter the brain and contribute to neurodegeneration. Removing or blocking cDC1s markedly reduced neurodegeneration and preserved cognitive performance despite persistence of tau pathology/tangles. 9

Interpretation: This dissociates the burden of tau aggregates from downstream tissue injury and cognition. Tau may establish the disease substrate, while adaptive immune attack helps determine how much neuronal and synaptic damage follows. Earlier mouse work likewise found that eliminating T cells or microglia blocked tau-associated neurodegeneration. 6

Dendritic tau quality control: A second study identifies a neuron-specific surface proteasome—the “neuroproteasome”—as a critical controller of tau proteostasis and tau paired-helical-filament formation, with effects influenced by age and APOE genotype. 2 Complementary work using single-molecule translation imaging shows endogenous mRNA translation can be mapped in dendrites in neurons and in vivo, supporting the central importance of local dendritic protein handling. 1

Act outside the brain: In principle, therapies could inhibit cDC1 antigen presentation, the cDC1–CD8 activation axis, or the migration/survival of the pathogenic CD8 population in peripheral lymph nodes. Such drugs might not need to cross the blood–brain barrier, potentially making delivery easier than CNS-targeted drugs. This remains a mouse-model implication—not an established Alzheimer’s treatment. 9

Preserve local tau disposal: A separate strategy would be to maintain or enhance dendritic neuroproteasome function, preventing locally synthesized tau from escaping rapid degradation and forming pathogenic assemblies. Because proteasomes have essential roles throughout the body, any approach would need neuron-, compartment-, and substrate-selective targeting rather than indiscriminate proteasome stimulation. 2

Combine mechanisms: The logic supports a two-pronged approach: reduce tau production/aggregation or improve its clearance, while also preventing peripheral immune priming from converting tau pathology into CD8-mediated brain damage. The studies do not yet establish whether either intervention is safe, effective, or durable in people.